Aspire Biopharma's Subsidiary, Buzz Bomb Caffeine Company, Appoints John Choe as Western Sales DirectorESTERO, FL / ACCESS Newswire / March 17, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire"), wholly owned subsidiary, Buzz Bomb Caffeine Company, has appointed 25-year industry veteran John Choe as Western Sales Director. Choe joins the leadership team with a distinguished career of scaling consumer brands and leading high-performance teams across the retail and beverage sectors.
Aspire Biopharma's Subsidiary to Feature BUZZ BOMB(TM) at The Health & Fitness Show 2026ESTERO, FL / ACCESS Newswire / March 12, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire"), wholly owned subsidiary, Buzz Bomb Caffeine Company, announces its participation at The Health & Fitness (HFA) Show, scheduled for March 16-18 at the San Diego Convention Center.
Aspire Biopharma's Buzz Bomb(TM) Caffeine Company Achieves Record Social Media Growth and Sales Surge Following World-Record Marathon SponsorshipBUZZ BOMB™ captures over 400,000 views and a spike in online revenue driven by strategic brand expansion and Ashley Paulson's historic record at the Jackpot Ultra Running Festival.
Aspire Biopharma Regains Full Compliance with Nasdaq Listing RequirementsCompany achieves minimum stockholders' equity rule; Nasdaq confirms matter is closed
Aspire Biopharma's Buzz Bomb Caffeine Company Names ChicExecs as Public Relations Agency of RecordESTERO, FL / ACCESS Newswire / February 19, 2026 / Aspire Biopharma Holdings, Inc. (
NASDAQ:ASBP) ("Aspire" or the "Company") today announced that its wholly owned subsidiary Buzz Bomb Caffeine Company - marketer of a proprietary caffeine supplement - has named ChicExecs as its public relations agency of record.
Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Meclizine (Generic Dramamine(R))New delivery system targets rapid-onset relief for motion sickness and vertigo, modernizing the $450M global market for the active ingredient in Dramamine®.
Aspire Biopharma Announces the Appointment of New Member to Its Board of DirectorsNew independent director Phillip Balatsos brings commercial and capital markets expertise to drive development patent-pending drug delivery platform
Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq RequirementsESTERO, FLORIDA / ACCESS Newswire / February 11, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today announced that it has entered into a securities purchase agreement on February 6, 2026 (the "Securities Purchase Agreement") with select institutional and accredited investors (collectively, the "Investors") for the purchase and sale of up to 26,250 shares of Series A Convertible Preferred Stock (each, a "Preferred Share" and collectively, the "Preferred Shares"), at a purchase price of $800 per Preferred Share. The Preferred Shares are convertible into shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"), representing aggregate gross proceeds to the Company of up to $21.0 million, before deducting placement agent fees and other offering expenses (the "Offering").
Aspire Biopharma Regains Compliance with Nasdaq Minimum Bid Price RequirementCompany achieves minimum $1.00 closing bid for 10 consecutive business days; Nasdaq confirms matter is closed
Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, to Showcase BUZZ BOMB(TM) Caffeine and its Innovative Sublingual Delivery Technology at The Sports & Active Nutrition SummitESTERO, FL / ACCESS Newswire / February 5, 2026 / Aspire Biopharma Holdings, Inc. (
NASDAQ:ASBP) ("Aspire" or the "Company"), wholly owned subsidiary, Buzz Bomb Caffeine Company, a marketer of a proprietary sublingual caffeine supplement today announced its participation at The Sports & Active Nutrition Summit USA, scheduled for February 18-20 in San Diego, CA. Aspire will feature its flagship caffeine product, BUZZ BOMB™, at the event.
Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, Partners with Blue Shark Beverages to Expand Southern California DistributionESTERO, FL / ACCESS Newswire / February 3, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), wholly owned subsidiary, Buzz Bomb Caffeine Company, today announced a strategic brand management and distribution agreement with Blue Shark Beverages. Effective February 1, the relationship is expected to drive the retail expansion of BUZZ BOMB™, a proprietary 50mg sublingual caffeine stick pack in four flavors, across key Southern California markets.
Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand IdentityStrategic inventory of 100,000 20-packs now available to meet increasing demand for rapid-onset sublingual caffeine technology
Aspire Biopharma's Unveils Bold New Era for BUZZ BOMB(TM) Caffeine with Dynamic Website and Packaging RedesignNew streamlined, mobile-optimized shopping experience, allows consumers to purchase BUZZ BOMB™ directly, access exclusive promotions and engage with the brand through educational and lifestyle content highlighting the benefits of sublingual delivery
Aspire Biopharma Announces Reverse Stock SplitESTERO, FL / ACCESS Newswire / January 14, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today announced a reverse stock split of its issued and outstanding common stock, par value $0.01 per share, at a ratio of one (1) share of common stock for every forty (40) shares of common stock, that will become effective as of 12:01 a.m. (Eastern Time) on January 16, 2026 (the "Effective Date"). The Company's common stock will begin trading on a split-adjusted basis when the market opens on January 16, 2026. At the Company's Special Meeting of Stockholders held on November 4, 2025, the Company's stockholders approved a proposal to authorize a reverse stock split of the Company's Common Stock, at a ratio within the range of 1-for-5 to 1-for-40. The Company's board of directors approved a 1-for-40 reverse split ratio, and on January 15, 2026, the Company will file a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect the reverse stock split effective January 16, 2026. The Company's common stock will continue to trade on The Nasdaq Capital Market under the stock ticker "ASBP" but will trade under the new CUSIP number 738920 206.
Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA)FDA feedback supports 505(b)(2) filing in H2 2026; No additional studies required beyond current planned 32-subject clinical trial
Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) CaffeineA highly decorated endurance athlete, Ashley embodies the grit, energy, and rapid performance that BUZZ BOMB® was designed to support
Brookmount Gold (OTC: BMXI) Profitable Q3 2025, Gold Production, Spinoff Dividends Takes Shape – More Stocks InsideBrookmount Gold, Inc. (OTC: BMXI) delivered a solid third quarter for fiscal 2025, underscoring its transformation into a profitable, expanding gold producer while setting the stage for several potentially value-unlocking catalysts in the months ahead.
Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing RequirementsESTERO, FL / ACCESS Newswire / December 12, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, received notice (the "Notice") on December 11, 2025, from the Nasdaq Listing Qualifications Panel (the "Hearings Panel") of The Nasdaq Stock Market LLC ("Nasdaq") that the Hearings Panel has granted the Company's request to continue its listing on The Nasdaq Stock Market, subject to the Company meeting certain conditions upon transfer of its common stock to The Nasdaq Capital Market, including demonstrating compliance with Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule") on or before January 30, 2026 and with Listing Rule 5550(b)(1) (the "Equity Rule") on or before February 17, 2026.
Aspire Biopharma Provides Q3 2025 Business UpdateESTERO, FL / ACCESS Newswire / December 4, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, today provides a business update for the quarter ended September 30, 2025.
Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)ESTERO, FLORIDA / ACCESS Newswire / December 2, 2025 / Aspire Biopharma Holdings, Inc. (
NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, is pleased to announce that on November 3, 2025, it submitted its Pre-IND meeting request and briefing package to the U.S. Food and Drug Administration (FDA). The submission concerns the Company's lead product candidate, a fast-acting, high-dose sublingual aspirin formulation for the treatment of suspected acute myocardial infarction (AMI) and represents a significant milestone on the path to potential FDA approval.
Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team MemberESTERO, FL / ACCESS Newswire / November 26, 2025 / Aspire Biopharma Holdings, Inc. (
NASDAQ:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, has expanded its scientific team with the November 4, 2025 addition of Mark J. Jaroszeski, PhD, a tenured professor in the Department of Medical Engineering at the University of South Florida. Dr. Jaroszeski, who holds a PhD in Engineering Science with a dissertation focused on mechanically facilitated cell-cell electrofusion.
